Summary
Eli Lilly and Company (LLY) filed an 8-K on December 21, 2006, reporting several key events. The most significant for investors is the amendment to the Agreement and Plan of Merger with ICOS Corporation, increasing the acquisition price per share to $34.00, a notable increase from the previous $32.00 offer. This suggests Lilly's commitment to acquiring ICOS and potentially reflects an updated valuation or competitive bidding situation. Additionally, the filing details the confirmed closure of the Basingstoke, England manufacturing facility, with restructuring charges estimated between $85-95 million. The majority of these charges are expected in Q4 2006, with non-cash asset impairment charges forming a significant portion. The company also announced a new equity program for executive officers called the Shareholder Value Award (SVA), replacing the stock option program and tying payouts to stock price growth over a three-year period. Executive compensation values for this new program were disclosed.
Key Highlights
- 1Lilly increased its offer to acquire ICOS Corporation from $32.00 to $34.00 per share via an amendment to the merger agreement.
- 2The company confirmed the closure of its Basingstoke, England manufacturing facility, with operations ceasing by December 31, 2007.
- 3Restructuring charges related to the Basingstoke closure are estimated at $85-95 million, primarily impacting Q4 2006 results.
- 4These charges include $20-25 million in cash-based severance and $65-70 million in non-cash asset impairment.
- 5Lilly introduced a new Shareholder Value Award (SVA) equity program for executive officers, replacing stock options.
- 6The SVA program links payouts to company stock price growth over a three-year performance period, with payouts ranging from 0% to 140% of target.
- 7Specific 2007 equity grant values were disclosed for top executive officers under the new SVA program.